STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts

Access Resources

Thank you for your interest in our resources. Please fill out the information here to have full access to our library of useful information, including what you are looking for currently.

Name(Required)

Work Email(Required)

Company(Required)

Your Region(Required)

Your Country

U.S. State

European Country

This field is hidden when viewing the form

Your Country

This field is hidden when viewing the form

U.S. State

This field is hidden when viewing the form

Territory

By submitting this form, you consent to receive communication from WuXi Biology regarding your request and acknowledge having received, read, and understood our Privacy Notice.

By submitting this data form, you consent to WuXi AppTec collecting and processing the information you provided for our internal use, in accordance with our Privacy Policy.

← Return to Resources

Access Resources

Related Content

Integrated Screening and Assay Capabilities Facilitate Peptide Drug Discovery

Overcoming PARP Inhibitor Resistance in an Olaparib-Induced Model

Contact An Expert Today!